ScinoPharm Taiwan Ltd (TWSE:1789), a process R&D and API manufacturing service provider to the global pharmaceutical industry, announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS).
According to ScinoPharm Taiwan, it is the only pharmaceutical company in Taiwan to achieve this milestone.
The company says that it is actively progressing regulatory submissions and forging collaborations across Europe, Asia, and emerging markets to expand its international presence in the generic drug product market and build on its already strong position on the generic API front.
Esco Aster partners with Shine-On Biomedical for HLA-G targeting exosome drug delivery platform
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism
Axsome Therapeutics secures FDA priority review for AXS-05 in Alzheimer's disease agitation
Vanda's NEREUS approved by US FDA for prevention of motion sickness
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Citius Pharmaceuticals reports full-year financial results
Bioeq and Zydus partner for US commercialisation of Lucentis biosimilar NUFYMCO
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA